Cantor Fitzgerald Comments on Precigen FY2025 Earnings

Precigen, Inc. (NASDAQ:PGEN) – Research analysts at Cantor Fitzgerald issued their FY2025 EPS estimates for shares of Precigen in a note issued to investors on Thursday, March 20th. Cantor Fitzgerald analyst J. Kim anticipates that the biotechnology company will post earnings per share of ($0.27) for the year. The consensus estimate for Precigen’s current full-year earnings is ($0.32) per share.

Precigen (NASDAQ:PGEN) last released its quarterly earnings data on Wednesday, March 19th. The biotechnology company reported ($0.04) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.06) by $0.02. Precigen had a negative return on equity of 123.06% and a negative net margin of 3,521.68%. The firm had revenue of $1.19 million during the quarter, compared to analysts’ expectations of $1.30 million.

Several other equities analysts have also weighed in on PGEN. JMP Securities reaffirmed a “market outperform” rating and set a $5.00 price objective on shares of Precigen in a research report on Tuesday, January 14th. HC Wainwright restated a “buy” rating and set a $6.00 price target on shares of Precigen in a report on Thursday. One investment analyst has rated the stock with a sell rating and four have assigned a buy rating to the company. Based on data from MarketBeat, Precigen presently has an average rating of “Moderate Buy” and a consensus price target of $7.00.

Precigen Price Performance

Shares of Precigen stock opened at $1.81 on Monday. The firm has a market cap of $532.22 million, a price-to-earnings ratio of -3.29 and a beta of 1.58. The stock has a 50-day simple moving average of $1.61 and a 200-day simple moving average of $1.15. Precigen has a 52-week low of $0.65 and a 52-week high of $2.17.

Institutional Investors Weigh In On Precigen

Several institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Envestnet Asset Management Inc. lifted its holdings in Precigen by 29.0% in the 4th quarter. Envestnet Asset Management Inc. now owns 26,343 shares of the biotechnology company’s stock worth $30,000 after purchasing an additional 5,915 shares during the last quarter. Invesco Ltd. lifted its holdings in Precigen by 14.6% in the 4th quarter. Invesco Ltd. now owns 47,307 shares of the biotechnology company’s stock worth $53,000 after purchasing an additional 6,040 shares during the last quarter. ProShare Advisors LLC lifted its holdings in Precigen by 26.6% in the 4th quarter. ProShare Advisors LLC now owns 51,822 shares of the biotechnology company’s stock worth $58,000 after purchasing an additional 10,900 shares during the last quarter. Stoneridge Investment Partners LLC lifted its holdings in Precigen by 21.3% in the 4th quarter. Stoneridge Investment Partners LLC now owns 68,681 shares of the biotechnology company’s stock worth $77,000 after purchasing an additional 12,063 shares during the last quarter. Finally, Wells Fargo & Company MN lifted its holdings in Precigen by 12.0% in the 4th quarter. Wells Fargo & Company MN now owns 114,558 shares of the biotechnology company’s stock worth $128,000 after purchasing an additional 12,285 shares during the last quarter. 33.51% of the stock is currently owned by institutional investors and hedge funds.

About Precigen

Precigen, Inc operates as a discovery and clinical-stage biopharmaceutical company that develops gene and cell therapies using precision technology to target diseases in therapeutic areas of immuno-oncology, autoimmune disorders, and infectious diseases. It operates through two segments, Biopharmaceuticals and Exemplar.